TABLE 1.
Clinicopathological features of the three cases.
| Case 1 | Case 2 | Case 3 | |
|---|---|---|---|
| Sex | Female | Female | Male |
| Age | 49 | 45 | 59 |
| Smoking | Never | Never | Never |
| Pathology | LADC | LADC | LADC |
| Mutation | EGFR missence mutation (E18) + EML4 (E6)‐ALK (E20) + TP53 mutation | EML4 (E20)‐ALK (E20) + TP53 mutation | HADHA (E4)‐ALK (E19) |
| Initial TNM Stage | IIIB (cT1N3M0) | IVB (cT4N3M1c) | IVB (cT4N3M1c) |
| Metastasis | — | Lung, bone, liver | Lung, bilateral adrenal, brain, bone |
| ECOG | 0 | 2 | 0 |
| Initial treatment |
PC*3 + P*1 + RT Ceritinib |
Ensartinib |
Ceritinib RT (brain lesion) |
| Initial response | PR | PR | PR |
| Initial mPFS | 22 months | 13 months | 8 months |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LADC, lung adenocarcinoma; mPFS, median progression‐free survival; P, pemetrexed; PC, pemetrexed and carboplatin; PR, partial response; RT, radiotherapy.